CRT-156 Current Perspectives on Stent Deformation: Trends, Characteristics and Outcomes From the Food and Drug Administration Manufacturer and User Facility Device Experience Database  by Omar, Alfazir et al.
S2 J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 7 , N O . 2 , S u p p l S , 2 0 1 4
T
O
P
T
E
NCORONARY-Coronary
CRT-156
Current Perspectives on Stent Deformation: Trends, Characteristics and Outcomes
From the Food and Drug Administration Manufacturer and User Facility Device
Experience Database
Alfazir Omar, Hideaki Ota, Lakshmana Pendyala, Joshua P. Loh, Marco A. Magalhaes,
Sa’ar Minha, Ricardo O. EscarcegaAlarcon, Nevin C. Baker, Wenjie Tian, Fang Chen,
Rebecca Torguson, Augusto Pichard, Lowell Satler, Ron Waksman
MedStar Heart Institute, Washington, DC
Background: Newer generation DES has been associated with thinner stent struts
and fewer connectors. We aimed to assess the contemporary incidence and clinical
implications of stent deformation (SD). The FDA Manufacturer and User Facility
Device Experience (MAUDE) database is an electronic system which aims to capture
voluntary reported device-related safety issues.
Methods: MAUDE database was searched from 2002-2013 for “stent deformation”,
“longitudinal deformation” and “longitudinal stent deformation”. We reviewed 1727
reports and identiﬁed 704 reports with SD.
Results: A total of 704 reports were identiﬁed with SD. There were 473 reports of
SD due to failure of stent implantation and stents were subsequently removed. The
majority for these cases involved lesions with at least moderate calciﬁcation and
moderate tortuousity. Most of this SD occurred in the Resolute platform (66.2%),
followed by Endeavor platform (29.4%), Element (3.4%), Cypher and Taxus Liberte
(1%). The remaining 231 reports were SD in successfully implanted stents. These
include 66 reports with at least moderate tortuosity, 64 reports with at least moderate
calciﬁcations, 45 reports involving bifurcations and 33 reports involving ostial lesions.
Most of this SD occurred in the Element platform (86.1%). The majority of SD was in
the LAD (40.3%), followed by RCA (22.5%), LCX (14.3%), vein graft (10%) and left
main (5.2%). The primary mechanisms for SD were associated with post-dilatation
balloon (25.7%), guide catheter (13.7%) or imaging device (13.6%). The majority of
patients was stable and was treated with another stent implantation (46.8%) or balloon
angioplasty (39.0%).
Conclusions: Majority of reported SD occurs in the newer generation DES.
Adequate lesion preparation and careful usage of device through stents are essential to
prevent incidence of SD.CORONARY-Coronary
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Background: The impact of optimal glycemic control on the long term cardiovascular
outcomes in diabetic patients is a subject of ongoing controversy that may be especially
pertinent in patients undergoing percutaneous coronary intervention (PCI).
Objective: This study aimed to determine the prognostic value of peri-procedural
glycosylated hemoglobin (HbA1C) levels in diabetic patients undergoing PCI with
2nd-generation drug-eluting stent (DES) implantation.
Methods: From July 2008 to May 2012, a cohort of 586 consecutive diabetic patients
that underwent PCI with implantation of 2nd generation DES at our center were
analyzed. Patients were stratiﬁed in to two groups based on HbA1C [A1C<7(n¼216)
and A1C7 (n¼370)]. One-year rate of major adverse cardiovascular events
(MACEs) including death, Q-wave myocardial infarction, and target vessel revascu-
larization was indexed.
Results: Baseline clinical and procedural characteristics were similar between groups,
except patients in A1C7 group were younger (6411 vs. 6810, p<0.001), had
higher insulin treated diabetes (55% vs. 26%, p<0.001), and higher body mass index
(337 vs. 316, p¼0.002). On the other hand patients in A1C<7 group had higher
baseline creatinine (1.82.1 vs. 1.41.6, p¼0.04) and higher dialysis (8% vs. 3%,
p¼0.006). The rates of one year MACEs (18% vs. 13%, p¼0.12), mortality (6.8% vs.
7.4%, p¼0.76) and revascularization (7.6% vs. 4.3%, p¼0.12) were similar in the high
A1C and normal A1C groups. By multivariate analysis, age, renal failure, and type C
lesion were independently associated with MACEs. In contrast, neither HbA1C nor
fasting plasma glucose were associated with outcome.
Conclusions: Peri-procedural HbA1C is no longer a correlate of cardiac events at
one year in diabetic patients with coronary artery disease undergoing PCI with
2nd-generation DES.
